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Over the last decade, we have gained new insight into the pathophysiology of cachexia
associated with pancreatic cancer. Unfortunately, its treatment is complex and remains
a challenge. Pancreatic cancer cachexia is a multifactorial syndrome characterized by
uncompensated adipose tissue and skeletal muscle loss in the setting of anorexia that
leads to progressive functional impairment. This paper will review the current concepts
of pancreatic cancer cachexia, its assessment and pathophysiology as well as current
and future treatments. The successful management of pancreatic cancer cachexia will
likely require a multimodal approach that includes nutritional support and combination
pharmaceutical interventions.
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INTRODUCTION
Cachexia is a ubiquitous characteristic of pancreatic cancer and
develops in approximately 80% of pancreatic cancer patients
during their disease course (Fearon et al., 2006b). Up to one-
third die from complications associated with cachexia through
immobility, severe respiratory muscle impairment resulting in
cardiopulmonary failure, and impaired immunity (Bachmann
et al., 2009). Cachexia is a complex metabolic disorder that
involves features of anorexia, anemia, and loss of adipose and
skeletal muscle mass. In pancreatic cancer patients, it has been
associated with reduced physical function, lower response rates
to chemotherapy and radiation treatment, and decreased sur-
vival (Dewys et al., 1980; Moses et al., 2004; Bachmann et al.,
2008, 2009). Pre-operative evidence of cachexia in pancreatic
cancer patients has been also associated with worse postoper-
ative outcome after pancreaticoduodenectomy (Pausch et al.,
2012).
Although new insights to the pathogenesis of pancreatic cancer
cachexia have been gained over the past decade, the underlying
mechanisms leading to this syndrome are not fully understood.
There continues to be an active search for potential targets and
effective treatment. This article reviews the current concepts and
management of this clinical dilemma.
DEFINITION AND CLASSIFICATION OF CANCER CACHEXIA
Cachexia has been recognized as a common complication of
cancer. In 2011, an international consensus defined cancer
cachexia as a multifactorial syndrome characterized by ongo-
ing loss of skeletal muscle mass that cannot be fully reversed
by conventional nutritional support and leads to progressive
functional impairment (Fearon et al., 2011). Diagnostic crite-
ria include weight loss greater than 5% over the past 6 months,
weight loss greater than 2% in individuals with body mass
index (BMI) less than 20 kg/m2, or evidence of sarcopenia
with any degree of weight loss greater than 2% (Table 1).
Evidence of sarcopenia is defined as appendicular skeletal mus-
cle index less than 7.26 kg/m2 in males and less than 5.45 kg/m2
in females determined by dual energy X-ray absorptiometry
(DEXA). Based on these criteria, the majority of pancreatic can-
cer patients have cachexia at the time of diagnosis (Fearon et al.,
2006b).
Cancer cachexia develops progressively through a spectrum.
The international consensus identified three stages of cachexia:
precachexia, cachexia, and refractory cachexia (Fearon et al.,
2011). Severity is classified based on the degree of depletion of
energy stores and body protein mass (using BMI) and the rate of
ongoing weight loss. In precachexia, patients demonstrate early
clinical and metabolic signs including anorexia and impaired
glucose tolerance preceding substantial involuntary weight loss.
Patients then develop progressive weight loss and meet the crite-
ria for cachexia as previously defined. Cachexia becomes clinically
refractory as a result of progressive cancer unresponsive to ther-
apy. In this stage, there is active catabolism, and patients have
worsening physical function with a life expectancy of less than 3
months.
ASSESSMENT OF CANCER CACHEXIA
Since cachexia is a multifactorial syndrome, its evaluation should
involve assessment for various features as summarized in Table 2:
anorexia or reduced food intake, catabolic drivers, muscle mass
and strength, and functional and psychosocial effects (Fearon
et al., 2011). Some of these different characteristics of cancer
cachexia have been found to be adverse prognostic indicators.
A recent study showed that weight loss (>10% weight loss),
reduced food intake (<1500 kcal/day), and evidence of systemic
inflammation [C-reactive protein (CRP) > 10mg/L] identified
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Table 1 | Diagnosis of cancer cachexia (Fearon et al., 2011).
Weight loss greater than 5% over the past 6 months; or
Weight loss greater than 2% in individuals with BMI less than 20 kg/m2; or
Evidence of sarcopenia* with weight loss greater than 2%
*Sarcopenia defined as appendicular skeletal muscle index in males <7.26 kg/m2
and in females <5.45 kg/m2determined by DEXA.
Table 2 | Assessment of cancer cachexia.
Areas of assessment Methods
Reduced food Patients estimate overall food intake
intake/ anorexia Third-party assessment of food intake
(family member)
Assess for mechanical factors contributing
to reduced intake
Hypercatabolism Serum CRP levels
Responsiveness to treatment and rate of
disease progression
Muscle mass and Cross-sectional imaging with CT or MRI
strength DEXA: appendicular skeletal muscle index
Anthropometry: mid-upper-arm muscle
area
Bioimpedance analysis: whole body fat-free
mass index
Physical and EORTC QLQ-C30
psychosocial
functioning
ECOG questionnaire
Karnofsky performance score
Electric activity meters
Checklists of specific activities
CRP, C-reactive protein; CT, computed tomography; MRI, magnetic resonance
imaging; DEXA, dual-energy X-ray absorptiometry; EORTC QLQ-C30, European
Organization for Research and Treatment of Cancer quality of life questionnaire
C-30; ECOG, Eastern Cooperative Oncology Group.
pancreatic cancer patients with reduced subjective and objective
functional ability. Patients with at least two of these components
had a significantly worse prognosis (Fearon et al., 2006b).
Evaluation of food intake should be routinely performed. At
the minimum, patients can be asked to estimate their overall food
intake in relation to normal intake with dietary or recall records.
Another simple method for prospective third-party assessment of
food intake is the percentile calculation of food consumed at each
meal by a family member (Bruera and Sweeney, 2000). Patients
should also be evaluated for underlying factors that contribute
to reduced food intake, such as lack of appetite, chemosensory
disturbances, dysphagia, decreased gastrointestinal (GI) motility,
pain, and fatigue.
A key component of pancreatic cancer cachexia is hyper-
catabolism due to direct tumor metabolism, systemic inflam-
mation, or other tumor-mediated effects. Hypercatabolism due
to systemic inflammation can be assessed using serum CRP
levels (Moses et al., 2009). Indirect indices of catabolism include
responsiveness to chemotherapy and rate of disease progression.
Cancer cachexia is characterized by ongoing skeletal muscle
loss. There are various methods for muscle mass assessment:
cross-sectional imaging with computed tomography (CT) or
magnetic resonance imaging (MRI); appendicular skeletal muscle
index obtained from DEXA; mid-upper-arm muscle area by
anthropometry; and whole body fat-free mass index determined
by bioimpedance analysis (Simons et al., 1995; Prado et al.,
2009; Fearon et al., 2011; Di Sebastiano and Mourtzakis, 2012).
Imaging-based methods of muscle mass assessment can quantify
changes in body composition, including skeletal muscle wasting,
altered distribution of body fat, and pathological accumulation
of lipids in various tissues. MRI can measure the volume of
the quadriceps muscle with a coefficient of variation < 1%.
Diagnostic CT scans can be used to estimate abdominal muscle
cross-sectional area at the L3 level, which can be extrapolated
to whole body lean body mass. These modalities are usually
reserved for research purposes and not routinely used in the
clinic.
A comprehensive approach, including history, physical exam-
ination, and various imaging studies can aid in recognizing the
phenomenon termed sarcopenic obesity or cachexia hidden in the
context of obesity. Even at the time of diagnosis, approximately
40% of overweight or obese pancreatic cancer patients have sub-
stantial ongoing skeletal muscle wasting (Tan et al., 2009). Early
detection of sarcopenic obesity is important because it has been
shown to be an independent prognostic factor for decreased
survival in pancreatic cancer patients (Tan et al., 2009).
Cancer cachexia can have a profound adverse effect on phys-
ical and psychosocial functioning. Patients report altered body
images, which can significantly impact emotions and relation-
ships. The method of choice for evaluating functional effects
of cancer cachexia is the routine use of patient-reported phys-
ical functioning. This assessment can be obtained using the
European Organization for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire (QLQ)-C30 or the
Eastern Cooperative Oncology Group (ECOG) questionnaire.
Physician-reported physical activity (Karnofsky performance
score) and objectivemethodologies such as electric activitymeters
or checklists of specific activities can also be used to assess phys-
ical functioning. A recent study with subjects wearing an electric
activity monitor showed that the level of physical activity in
cachectic cancer patients is reduced by about 40% (Dahele et al.,
2007).
MECHANISMS OF CANCER CACHEXIA
The pathophysiology of cancer cachexia is characterized by neg-
ative protein and energy balance driven by a combination of
reduced food intake and increased metabolism (Fearon, 2008,
2012; Fearon et al., 2011). This process involves complex inter-
actions between the host and the tumor (Figure 1). There are
mechanical factors that contribute to reduced food intake. There
is evidence that anorexia and hypercatabolism are driven by
cytokines, circulating hormones, neuropeptides, neurotransmit-
ters, and tumor-derived factors. In addition, recent studies have
discovered other potentially significant processes involved in pan-
creatic cancer cachexia, including neural invasion and abnormal-
ities in the muscle microenvironment. This section will review
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FIGURE 1 | Proposed mechanisms of pancreatic cancer cachexia.
current proposed mechanisms that lead to the development of
this disease process.
MECHANICAL FACTORS
Reduced food intake can promote andmaintain cancer-associated
weight loss (Wigmore et al., 1997b). Mechanical digestive abnor-
malities can result in a lack of appetite and reduced food
intake. Patients with pancreatic cancer suffer from pain, fatigue,
nausea, dysphagia, gastroparesis, duodenal stenosis, pancreatic
insufficiency and malabsorption, and constipation (Deutsch
and Kolhouse, 2004). These symptoms are the direct conse-
quence of tumor invasion, which can result in the obstruc-
tion of the pancreatic duct and/or GI tract, particularly the
second portion of the duodenum. Many patients will undergo
pancreaticoduodenectomy for the resection of a pancreatic head
mass. This procedure can worsen pancreatic insufficiency and
decrease oral intake.
CYTOKINES AND SYSTEMIC INFLAMMATION
Systemic inflammation plays an important role in the patho-
physiology of pancreatic cancer cachexia. Elevated CRP levels
(CRP> 10mg/L), an indirect measure of systemic inflammation,
has been associated with cachexia and poor prognosis in pan-
creatic cancer patients (Fearon et al., 2006b). Elevated cytokine
levels, including IL-6 and IL-10, have been associated with poor
performance, weight loss, and decreased survival in pancreatic
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cancer patients (Ebrahimi et al., 2004; Moses et al., 2009). Recent
evidence strongly suggest that cytokines produced by tumor cells
or released by the host as a response to the cancer affect var-
ious pathways that lead to anorexia and a hypercatabolic state
(Figure 1). These pathways can be divided into central pathways,
which are hypothalamus-mediated, and peripheral pathways,
which involve direct lipolysis and proteolysis.
Centrally-mediated pathways
Under normal conditions, energy homeostasis is a highly reg-
ulated system of controls. The hypothalamus controls energy
intake by integrating peripheral signals that convey informa-
tion on energy and adiposity status. These inputs are transduced
into neuronal responses and, via signaling pathways, behavioral
responses. Current evidence suggests that systemic inflammation
plays a critical role in inducing cancer anorexia by triggering
a complex neurochemical cascade (Laviano et al., 2003; Fearon
et al., 2013; Suzuki et al., 2013; Tuca et al., 2013). Increased
cytokine expression from tumor growth prevents the hypotha-
lamus from responding appropriately to peripheral signals by
persistent stimulation of anorexigenic pathways and inhibition of
orexigenic pathways (Suzuki et al., 2013; Tuca et al., 2013).
Cancer anorexia may be partially due to derangement of
peripheral signaling transduction into neuronal responses by the
hypothalamus. There are two pathways that control energy expen-
diture and food intake within the hypothalamus: neuropeptide
Y (NPY)/Agouti-related peptide (AgRP) neurons that stimulate
energy intake and pro-opiomelanocortin (POMC)/cocaine and
amphetamine-regulated transcript (CART) neurons that inhibit
intake. Some studies suggest that cancer cachexia is associated
with hyperactivation of the POMC/CART pathway which may be
triggered by IL-1 and other pro-inflammatory cytokines (Wisse
et al., 2001; Marks and Cone, 2003; Marks et al., 2003; Scarlett
et al., 2007).
Leptin is a protein involved in regulating energy intake and
expenditure. Leptin reduces appetite and increases energy expen-
diture via the central nervous system (CNS). Through feed-
back signaling, leptin controls the production, and activation
of hypothalamic neuropeptides that regulate food intake and
energy expenditure, including NPY and corticotropin-releasing
factor (CRF). Since leptin is primarily released by adipose tis-
sue, decreased body fat mass or starvation leads to a decrease
in leptin levels. Low leptin levels allow for increased production,
release, and action of NPY, a potent orexigenic peptide, which
subsequently results in the activation of the NPY/AgRP path-
way. Additionally, low leptin levels result in decreased activity
of anorexigenic neuropepetides, such as CRF and melanocortin.
Studies have demonstrated that cytokines, such as tumor necrosis
factor-alpha (TNF-α) and interleukin1 (IL-1) increase the expres-
sion of leptin mRNA in adipocytes and plasma levels of leptin
despite starvation (Grunfeld et al., 1996; Janik et al., 1997; Sarraf
et al., 1997; Finck et al., 1998). Therefore, an increased leptin level
may contribute to cancer anorexia by preventing the normal com-
pensatory mechanisms that should occur with decreased food
intake. However, other studies have shown that these cytokines
can induce anorexia even in the absence of leptin (Faggioni et al.,
1997). Animal and clinical studies have also demonstrated that
leptin levels are not elevated in tumor-bearing rats and patients
with cancer cachexia (Simons et al., 1997; Wallace et al., 1998;
Mantovani et al., 2000; Bing et al., 2001). Recent evidence suggests
that in cancer cachexia IL-1 and TNF-α mimic leptin signaling
and interfere with the orexigenic response to reduced leptin levels
(Inui, 1999; Suzuki et al., 2013). Therefore, even with decreased
adiposity, there continues to be suppression of the orexigenic
response and stimulation of the anorexigenic pathway, resulting
in unopposed anorexia and increased energy expenditure.
Serotonin may also play an important role in the development
of cancer anorexia through the melanocortin system. Studies have
established that IL-1 stimulates the release of hypothalamic sero-
tonin (Shintani et al., 1993). Elevated serotonin levels, in turn,
contribute to the persistent activation of POMC/CART neurons,
resulting in decreased appetite and anorexia (Heisler et al., 2002).
Studies have demonstrated elevated plasma and cerebrospinal
fluid concentrations of tryptophan, a precursor of serotonin, in
patients with evidence of cancer cachexia compared to healthy
controls or cancer patients without cachexia (Cangiano et al.,
1990). Plasma tryptophan concentration normalized, and food
intake improved after tumor removal (Cangiano et al., 1994).
These findings suggest that hypothalamic serotonin may be an
important factor in the pathogenesis of cancer cachexia and a
potential therapeutic target.
These hypothalamic pathways and neuropeptides also have
catabolic effects. The POMC/CART anorexigenic pathway
increases the sympathetic nervous system activity, which causes
induction of mitochondrial uncoupling proteins, such as UCP-1
and UCP-2 (Li et al., 2002; Arruda et al., 2010). UCP-1 channels
protons across the inner mitochondrial membrane without ATP
production, resulting in thermogenesis and energy expenditure in
brown adipose tissue (Li et al., 2002; Arruda et al., 2010).
Peripheral pathways
Cytokines not only corroborate and sustain the neurochemical
changes responsible for anorexia, they have also been shown to
induce lipolysis, muscle catabolism, and the hepatic acute phase
protein response (APPR) through various pathways. These pro-
cesses lead to the development of uncompensated loss of muscle
and adipose tissue mass.
TNF-α. TNF-α was first identified as a cachexia-inducing factor
in chronic diseases. It may have properties that promote lipol-
ysis, impair lipogenesis, and induce muscle degradation. It has
been shown to induce lipolysis in vitro with increases in glycerol
release in mouse and human adipocytes, likely through down-
regulation of perilipin expression (Rydén et al., 2004). Perilipin
coats intracellular lipid droplets and acts as a barrier to lipolysis.
Decreased perilipin expression subsequently enables hormone-
sensitive lipase (HSL), a key regulator of lipolysis, to access the
surface of lipid droplets for breakdown (Zhang et al., 2002; Rydén
et al., 2004). TNF-α also has an inhibitory effect on adipocyte dif-
ferentiation, resulting in impaired lipogenesis (Cawthorn et al.,
2007; Hammarstedt et al., 2007).
Animal studies also suggest that TNF-α is involved in muscle
loss in cancer cachexia. Mouse models have shown that TNF-α
may induce muscle protein degradation through formation of
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reactive oxygen species (ROS). Oxidative stress results in the
activation of nuclear factor κB (NFκB) which, in turn, acti-
vates the ubiquitin-proteasome pathway (Llovera et al., 1998; Li
and Reid, 2000). Moreover, TNF-α has been shown to increase
expression of the 1.2- and 2.4-kb transcripts of ubiquitin and
the ubiquitin ligase atrogin 1/MAFbx in skeletal muscle (Llovera
et al., 1998; Li and Reid, 2000). In addition to protein degradation,
TNF-α has been shown to inhibit myogenesis in vitro through
NFκB-mediated downregulation of MyoD transcripts (Guttridge
et al., 2000).
Although these findings suggest a role for TNF-α in lipolysis
and proteolysis, its importance in cancer cachexia is an active
area of debate. Results from studies measuring levels of TNF-
α in patients with cancer cachexia have been conflicting. Some
studies have shown detectable levels of TNF-α in the serum of
pancreatic cancer patients with TNF-α levels inversely correlat-
ing with body weight and BMI; other studies involving patients
with advanced cancers have shown no correlation between cir-
culating TNF-α levels, weight loss, and anorexia (Maltoni et al.,
1997; Karayiannakis et al., 2001; Rydén et al., 2008). Therefore,
the origin and relevance of TNF-α to cancer cachexia remains
unclear.
IL-6. IL-6 is another important cytokine in pancreatic cancer
cachexia. IL-6 secretion is induced by TNF-α; it acts synergisti-
cally with TNF-α in many of its actions including stimulation of
other cytokines. Circulating levels of IL-6 correlate with weight
loss and reduced survival in pancreatic cancer patients (Ebrahimi
et al., 2004; Martignoni et al., 2005; Moses et al., 2009). Although
the role of IL-6 in lipolysis is not well established, a recent study
has shown enhanced IL-6 signaling in brown adipose tissue in
cachectic tumor-bearing mice suggesting that it may play a direct
role in the activation of thermogenesis (Tsoli et al., 2012). More
importantly, IL-6 is known to activate the hepatic APPR and
trigger tissue catabolism. The murine C-26 cachexia model has
shown that increasing levels of IL-6 correlated with the develop-
ment of cachexia; treatment with an IL-6 neutralizing antibody
attenuated the development of weight loss (Strassmann et al.,
1992). Moses et al. found that pancreatic cancer patients with
cachexia had elevated CRP levels and stimulated IL-6 production
(Moses et al., 2009). Although various cytokines and hormones
affect hepatocyte protein metabolism, IL-6 is known as the prin-
cipal regulator of APPR in human hepatocytes (Castell et al.,
1990). There is a strong correlation between increased periph-
eral blood mononuclear cells (PBMC) production of IL-6 and the
presence of elevated APPR (Martignoni et al., 2005, 2009; Moses
et al., 2009). The activation of hepatic APPR subsequently results
in hypercatabolism through reprioritization of body protein
metabolism from skeletal muscle to production of acute phase
proteins (Fearon et al., 1999). There appears to be a two- to three-
fold increase in fibrinogen production and increase in serumCRP
levels (Preston et al., 1998). Production of these acute phase pro-
teins by the liver is associated with mobilization of peripheral
amino acid stores primarily from skeletal muscle contributing to
the loss of lean tissue and catabolism. Overproduction of IL-6 and
elevated APPR have been associated with decreased survival in
patients with pancreatic cancer cachexia (Moses et al., 2009).
TUMOR-DERIVED FACTORS
In addition to cytokines and systemic inflammation, tumor-
derived factors contribute to metabolic abnormalities that give
rise to pancreatic cancer cachexia. Two of the most well stud-
ied factors are lipid mobilizing factor (LMF) and proteolysis-
inducing factor (PIF). The presence and role of other factors
that contribute to pancreatic cancer cachexia are currently being
investigated.
Lipid mobilizing factor
Todorov et al. isolated a LMF from a cachexia-inducing murine
tumor (MAC16 adenocarcinoma) model and the urine of
patients with unresectable pancreatic cancer and weight loss
(Todorov et al., 1998). The material was 43 kDA and was
found to be homologous with the plasma protein zinc-α2-
glycoprotein (ZAG) (Todorov et al., 1998). Pancreatic can-
cer patients with weight loss generally had LMF/ZAG in
the urine, but it was absent from patients without weight
loss or normal subjects (Todorov et al., 1998). A recent
study identifying serum proteins involved in pancreatic can-
cer cachexia identified LMF/ZAG as a possible marker (Felix
et al., 2011). Moreover, immunohistochemical analysis demon-
strated LMF/ZAG expression in pancreatic cancer cells and
in the peritumoral stroma (Felix et al., 2011). Patients with
cachexia had stronger immunostaining compared to pancreatic
cancer patients without cachexia or normal subjects (Felix et al.,
2011).
In vivo studies have shown that LMF/ZAG causes selective loss
of carcass fat without change in body water or nonfat mass (Hirai
et al., 1998). LMF/ZAG directly induces lipolysis by stimulat-
ing adenylate cyclase in a GTP-dependent process; this process
is postulated to be mediated by β3 adrenergic receptors (Hirai
et al., 1998; Khan and Tisdale, 1999; Russell et al., 2002). Hirai
et al. showed an increase in serum levels of glycerol and 3-
hydroxybutyrate after treating mice with LMF/ZAG. They also
showed a significant increase in oxygen uptake by brown adi-
pose tissue suggesting that LMF/ZAG promotes lipid utilization
(Hirai et al., 1998). In addition, LMF/ZAG has been shown to
increase lipid oxidation using the production of 14CO2 from
[14C-carboxy]triolein (Russell and Tisdale, 2002). This function
is achieved by directly activating the expression of mitochondrial
UCPs. LMF/ZAG induces increased expression of UCP-1, UCP-
2, and UCP-3 in brown adipose tissue, and UCP-2 in skeletal
muscle and liver (Bing et al., 2002). The effect of LMF/ZAG on
lipid oxidation and utilization is also likely mediated by β3 adren-
ergic receptors. LMF/ZAG also increases the sensitivity of white
adipose tissues to the lipolytic effects of other stimuli, including
catecholamines (Islam-Ali et al., 2001). Adipocyte plasma mem-
branes have Gs α-subunits and Gi α-subunits, which stimulate
and inhibit adenylate cyclase, respectively. LMF/ZAG increases
Gαs expression and decreases Gαi expression, which favor mobi-
lization of lipid stores from adipocytes and facilitate a catabolic
state (Islam-Ali et al., 2001). LMF/ZAG not only increases lipid
mobilization through various pathways but it also increases sub-
strate utilization and activates mitochondrial oxidative pathways
in brown adipose tissue resulting in lipolysis, increased energy
expenditure, and hypercatabolism.
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PROTEOLYSIS-INDUCING FACTOR
PIF was discovered in 1996 using a MAC16 adenocarcinoma
mouse model of cachexia. Todorov et al. reported the discov-
ery of a glycoprotein of molecular mass 24 kDa that produced
cachexia in vivo by inducing skeletal muscle catabolism (Todorov
et al., 1996). The samematerial was isolated from urine of cachec-
tic cancer patients, but not from patients with weight loss due
to trauma, cancer patients with little or no weight loss, and
normal subjects. PIF was detected in the urine of 80% of pan-
creatic cancer patients with significantly greater total weight loss
and rate of weight loss than patients who did not have PIF in
their urine (Wigmore et al., 2000b). Immunochemistry demon-
strated that the 24 kDa material is present in the cytoplasm
of GI tumors, including pancreatic adenocarcinoma (Cabal-
Manzano et al., 2001). Enzymatic degradation of PIF suggests
that it consists of a peptide core with molecular weight 4000Da
that is extensively N- and O-glycosylated to give a total molec-
ular mass of 24 kDa (Todorov et al., 1997). Examination of
the sequence of the human genome revealed the gene for the
polypeptide core of PIF is located in chromosome 12; two pro-
teins, dermicidin and Y-P30, have been reported to have 100%
homology (Schittek et al., 2001; Cunningham et al., 2002).
However, enzymatic degradation has shown that the oligosac-
charide chains are essential for the biologic activity of PIF
(Todorov et al., 1997).
When administered intravenously to normalmice, PIF isolated
from urine of cancer cachexia patients induced cachexia without
reduction in food and water intake (Cariuk et al., 1997). Analysis
of body composition demonstrated that the majority of weight
loss involved loss of lean body mass (Cariuk et al., 1997). This
decrease in lean body mass had two components: an increase
in protein degradation by 50% and a decrease in protein syn-
thesis by 50% observed in gastrocnemius muscle (Lorite et al.,
1997). Some studies suggest that PIF-mediated protein degrada-
tion may involve the ubiquitin-proteasome proteolytic pathway.
Administration of PIF to normal mice caused an increase in
mRNA levels for ubiquitin, E214k and the C9 proteasome subunit.
Therefore, protein degradation likely occurs through increased
expression of the ubiquitin-proteosome pathway in skeletal mus-
cle; this process is thought to be mediated by the activation of
NFκB (Lorite et al., 2001; Whitehouse and Tisdale, 2003; Wyke
and Tisdale, 2005). PIF has also been shown to induce total pro-
tein degradation and myosin depletion while actin levels remain
unchanged (Wyke and Tisdale, 2005).
The mechanism for NFκB activation by PIF is not fully
understood. It does involve release of arachidonic acid from
membrane phospholipids with rapid metabolism to eicosanoids
by phospholipase A2 (PLA2) (Smith and Tisdale, 2003). PIF
has been shown to increase expression of PLA2 (Smith and
Tisdale, 2003). One of the eicosanoids formed in response to PIF,
15-hydroxyeicosatetraenoic acid (15-HETE), can induce muscle
degradation in murine muscle cells (Wyke et al., 2005). 15-
HETE may be involved in the activation of protein kinase C
(PKC), which is important in the activation of NADPH oxidase
(Whitehouse et al., 2003; Smith et al., 2004; Wyke et al., 2005).
Activation of NADPH oxidase and generation of ROS play a
key role in PIF-induced expression of the ubiquitin-proteasome
pathway leading tomuscle degradation (Smith et al., 2004; Russell
et al., 2007). Increased ROS activates IκB kinase (IKK) which leads
to phosphorylation and degradation of IκB; this process, in turn,
releases NFκB from its inactive cytosolic complex (Smith et al.,
2004).
PIF not only results in protein degradation, it also causes
inhibition of protein synthesis. PIF induces the activa-
tion/phosphorylation of double-stranded RNA-dependent
protein kinase (PKR) (Eley and Tisdale, 2007). The activation of
PKR leads to the phosphorylation of eIF2, which inhibits transla-
tion initiation and protein synthesis (Eley and Tisdale, 2007). In
addition, PKR is known to activate IKK resulting in the nuclear
accumulation of NFκB and increased expression and activity of
the ubiquitin-proteasome pathway (Zamanian-Daryoush et al.,
2000).
In addition to its direct effects on skeletal muscles, PIF may
play a role in increasing hepatic cytokine production. Treatment
of cultures of human hepatocytes with PIF resulted in activation
of NFκB and signal transducers and activators of transcription
(STAT3), which caused an increased production of IL-6, IL-8, and
CRP, as well as decreased production of transferrin (Watchorn
et al., 2001). A similar effect was observed in human Kupffer cells
and monocytes and resulted in increased production of TNF-α,
IL-6, and IL-8 (Watchorn et al., 2005). PIF may likely contribute
to APPR seen in pancreatic cancer cachexia.
OTHER PROPOSED MECHANISMS
Pax7 dysregulation
A recent study provides evidence for a different pathway
involved in pancreatic cancer related muscle wasting. Pax7 is
a self-renewing transcription factor expressed in various mus-
cle cells, including satellite cells and other myogenic pro-
genitor cells. He et al. demonstrated that NFκB activation
in satellite cells resulted in the dysregulation of Pax7, which
suppressed expression of MyoD and myogenin (Olguin and
Olwin, 2004; He et al., 2013). This process subsequently
blocked myogenic differentiation and inhibited myoblast fusion
leading to impaired regeneration and muscle wasting (He
et al., 2013). They also demonstrated that Pax7 was induced
by serum factors from cachectic mice and pancreatic can-
cer patients in an NFκB-dependent manner both in vitro
and in vivo (He et al., 2013). However, it remains unclear
what circulating factors lead to NFκB activation and Pax7
dysregulation.
Neural invasion
Recent studies have shown that neural invasion, which commonly
occurs in pancreatic cancer, is related to cachexia and astrocyte
activation in pancreatic cancer patients (Mitsunaga et al., 2008;
Imoto et al., 2012). Nerve damage from intraneural tumors of
pancreatic cancer can activate astrocytes and microglia in the
spinal cord. These activated astrocytes subsequently induce lipol-
ysis and muscle atrophy, although the mechanisms leading to
cachexia require further investigation (Imoto et al., 2012). These
activated astrocytes may increase sympathetic nervous system
activity, which is known to cause lipolysis in adipose tissue and
muscle atrophy (Li et al., 2002).
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MANAGEMENT OF CANCER CACHEXIA
Clinical management of cachexia is currently limited and
complex. Best supportive care practices are important in
managing secondary causes of anorexia including pain, nausea,
pancreatic insufficiency, and constipation. In addition, current
treatment strategies are based on the following factors: onco-
logical therapy with optimal control of the tumor; nutritional
support; and pharmacological treatment. Since cancer cachexia is
a multifactorial syndrome, successful treatment will likely involve
a multimodal approach.
NUTRITIONAL SUPPORT
Nutritional risk is highest among pancreatic cancer patients
(Bozzetti and Group, 2009). Early involvement of dieticians and
nutrition assessment programs are essential to guide manage-
ment. Nutritional support is an integral part of pancreatic cancer
cachexia management and involves providing dietary advice, oral
nutritional supplementation, enteral nutrition, and parenteral
nutrition (Ottery, 1996; Nitenberg and Raynard, 2000; Jatoi and
Loprinzi, 2001; el-Kamar et al., 2003).
Dietary recommendations can significantly increase oral
caloric and protein intake (Ovesen et al., 1993). Several stud-
ies evaluating the role of oral nutritional supplementation
among patients with pancreatic cancer demonstrated improve-
ment in weight and appetite (Fearon et al., 2003; Bauer and
Capra, 2005). Oral supplementation with compounds such as
L-Carnitine and omega-3 fatty acids may have benefits as
well (Barber et al., 1999; Kraft et al., 2012). A small mul-
ticenter randomized double-blind trial demonstrated a sig-
nificant improvement in weight and body mass composition
as well as quality of life with L-Carnitine supplementation
in patients with advanced pancreatic cancer (Kraft et al.,
2012).
In patients with swallowing difficulties or severe dysphagia,
a complete enteral diet can be administered using a nasogas-
tric tube or gastrostomy tube. Enteral feeding can be associated
with significant morbidity due to aspiration, pneumonia, and
diarrhea. In a select group of patients with bowel dysfunction
and progressive weight loss despite enteral support, parenteral
nutrition may provide a temporary benefit or stabilization in
nutritional status (Pelzer et al., 2010).
Artificial nutrition can limit nutritional deterioration in
cachectic cancer patients and improve certain metabolic and
nutritional indices. However, the nutritional response is typi-
cally limited. It is also lower than responses observed in mal-
nourished non-cancer patients receiving equivalent artificial
nutrition (Nixon et al., 1981). Patients with pancreatic cancer
cachexia require a multimodal approach to disease management
(DeWys, 1979).
PHARMACOLOGICAL APPROACH
Various drugs have been studied in the treatment of cancer
cachexia. Their mechanisms of action are based on modulation
of cytokines, hormones, or other pathways involved in the patho-
physiology of cancer cachexia. Table 3 summarizes drugs and
their pharmacologic activity with proven or potential effects on
pancreatic cancer cachexia.
Progestogens
Megestrol acetate is a semi-synthetic progesterone currently used
as an appetite stimulant. When megestrol acetate was first intro-
duced in the treatment of disseminated breast and endometrial
cancer, patients developed weight gain and increased appetite
as a side effect. Multiple trials demonstrated that megestrol
acetate (480–800 mg/day) resulted in significant improvement in
appetite, food intake, nausea, and weight gain among patients
with cancer cachexia, including those with pancreatic cancer
(Bruera et al., 1990; Loprinzi et al., 1990, 1993a; Westman
et al., 1999; Deutsch and Kolhouse, 2004). In 1993, the Food
and Drug Administration (FDA) approved megestrol acetate for
the treatment of cancer anorexia-cachexia syndrome as well as
cachexia due to chronic conditions, including human acquired
immunodeficiency syndrome (AIDS). Megestrol acetate is typi-
cally well-tolerated with low incidence of adverse effects, such as
rash, adrenal insufficiency, hyperglycemia, and thromboembolic
events. The increase in thromboembolism has an incidence of less
than 5% (Loprinzi et al., 1990). Since its approval, various meta-
analyses have confirmed that megestrol acetate increases appetite,
weight, and quality of life compared to placebo or other drugs
potentially active in the management of cancer cachexia (cis-
apride, dronabinol, corticosteroids, nandrolone) (Pascual López
et al., 2004; Les´niak et al., 2008). The efficacy of megestrol acetate
appears to be dose-dependent (Loprinzi et al., 1993a). Based on
body composition analysis, megestrol acetate causes weight gain
predominantly from an increase in adipose tissue and less from
an increase in body fluid (Loprinzi et al., 1993b). There was no
improvement in survival demonstrated in patients treated with
megestrol acetate (Westman et al., 1999; Les´niak et al., 2008).
The pharmacologic activity of megestrol acetate in appetite
stimulation and weight gain may be related to decreased pro-
duction and release of pro-inflammatory cytokines (IL-1, IL-6,
TNF-α) and stimulation of NPY in the hypothalamus (McCarthy
et al., 1994; Mantovani et al., 1998a,b). Another progestogen,
medroxyprogesterone acetate, was shown to decrease in vitro pro-
duction of cytokines and serotonin by PBMC of cancer patients
(Mantovani et al., 1998a,b).
Corticosteroids
Corticosteroids are effective in inducing an increase in appetite,
food intake, weight gain, and sense of well-being (Willox et al.,
1984; Bruera et al., 1985; Loprinzi et al., 1999). However, the
effects are short lived (less than 4 weeks) and associated with
long-term side effects, such as insulin resistance, fluid retention,
steroid-induced myopathy, skin fragility, adrenal insufficiency,
and sleep and cognitive disorders (Loprinzi et al., 1999). The
mechanism of action in cancer cachexia is not well understood
but is likely related to the inhibition of IL-1, TNF-α, and lep-
tin as well as the stimulation of NPY (Plata-Salamán, 1991).
Because of their short term symptomatic benefits but long term
adverse effects, corticosteroids may be useful in patients with
short expected survival.
Cannabinoids
Dronabinol is effective in reducing nausea and increasing appetite
with associated weight stabilization. A phase II trial showed that
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Table 3 | Pharmacological approach to pancreatic cancer cachexia.
Drugs Mechanism of action References Level of
evidence
Progestogens
(megestrol acetate and
medroxyprogesterone acetate)
Appetite stimulation
Decrease production and release of cytokines (IL-1,
IL-6, TNF-α)
Stimulation of NPY
Decrease production of serotonin in PBMC
Bruera et al., 1990; Loprinzi et al., 1990,
1993a,b; McCarthy et al., 1994; Mantovani
et al., 1998a,b; Westman et al., 1999;
Deutsch and Kolhouse, 2004; Pascual
López et al., 2004; Les´niak et al., 2008
I
Corticosteroids
(prednisone, dexamethasone,
methylprednisolone)
Appetite stimulation
Not well understood
Likely from inhibition of IL-1, TNF-α, and leptin
Stimulation of NPY
Willox et al., 1984; Bruera et al., 1985;
Plata-Salamán, 1991; Loprinzi et al., 1999;
I
Cannabinoids
(dronabinol)
Appetite stimulation, anti-emetic
Interaction with endorphin receptors
Interference with IL-1 synthesis
Activation of cannabinoid receptor involved in the
neurochemical circuit of leptin
Inhibition of prostaglandin synthesis
Nelson et al., 1994; Jatoi et al., 2002 II
NSAIDs
(COX-2 inhibitors, indomethacin,
ibuprofen)
Anti-inflammatory
Decrease production and release of acute phase
proteins and pro-inflammatory cytokines
Inhibit prostaglandin synthesis
Gelin et al., 1991a,b; Lundholm et al.,
1994; McMillan et al., 1995, 1997, 1999;
Preston et al., 1995; Wigmore et al., 1995;
Lai et al., 2008
II
Thalidomide Anti-inflammatory and immunomodulatory
properties
Downregulate production of TNF-α and other
cytokines
Inhibit NFκB
Downregulate COX-2
Inhibit angiogenesis
Sampaio et al., 1991; Bruera et al., 1999;
Gordon et al., 2005
II
Omega-3 fatty acids
(eicosapentaenoic acid)
Anti-inflammatory and immunomodulatory
properties
Decrease production of cytokines (IL-1, IL-6, TNF-α)
Inhibit downstream effects of LMF and PIF
Tisdale and Beck, 1991; Meydani et al.,
1993; Tisdale, 1996; Wigmore et al., 1996,
1997a, 2000b; Barber et al., 1999; Hussey
and Tisdale, 1999; Jatoi et al., 2004;
Fearon et al., 2006a
Conflicting
NSAIDs, non-steroidal anti-inflammatory drugs; NPY, neuropeptide Y; IL-1, interleukin-1; IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha; PBMC, peripheral
blood mononuclear cells; NFκB, nuclear factor κB; COX-2, cyclooxygenase-2; LMF, lipid mobilizing factor; PIF, proteolysis-inducing factor.
dronabinol reduced anorexia in 68% of patients, but 16% of
patients had to suspend treatment due to toxicity (Nelson et al.,
1994). Dronabinol has many adverse effects on the CNS. The
main side effects include euphoria, hallucinations, psychosis, ver-
tigo, and cardiovascular disorders. Appetite stimulation appears
to be mediated by interaction with endorphin receptors, inter-
ference with IL-1 synthesis, activation of cannabinoid receptors
involved in the neurochemical circuit of leptin, and prostaglandin
synthesis inhibition.
A controlled clinical trial by Jatoi et al. compared megestrol
acetate and dronabinol in patients with cancer cachexia (Jatoi
et al., 2002). A total of 469 patients were treated with megestrol
acetate 800 mg/day or dronabinol 2.5mg/12 h or both. There
was a greater increase in appetite and weight in the megestrol
acetate group compared to the dronabinol group: 75 vs. 49%
(P = 0.0001) for appetite, respectively and 11 vs. 3% (P = 0.02)
for weight gain of at least 10% from baseline, respectively (Jatoi
et al., 2002). The combination treatment group resulted in no sig-
nificant differences in appetite and weight when compared to the
megestrol acetate only group (66 vs. 75%, P = 0.17, for appetite
and 8 vs. 11%, P = 0.43, for =10% weight gain, respectively).
Megestrol acetate appears to be superior to dronabinol although
the cannabinoid is still able to trigger an increase in appetite
and reduction in nausea. It serves as an alternative option as an
appetite stimulant and anti-emetic.
Anti-inflammatory agents
Systemic inflammation is an important contributor to the patho-
physiology of pancreatic cancer cachexia. Pro-inflammatory
cytokines, such as TNF-α, IL-1, and IL-6, have been implicated
in the development of cancer cachexia and have been shown
to exhibit synergistic effects. Therefore, multiple therapeutic
Frontiers in Physiology | Gastrointestinal Sciences March 2014 | Volume 5 | Article 88 | 8
Tan et al. Pancreatic cancer cachexia
strategies have been developed to curtail the inflammatory
response by blocking the synthesis or action of cytokines.
Non-steroidal anti-inflammatory drugs (NSAIDs), includ-
ing cyclooxygenase-2 (COX-2) inhibitors, indomethacin, and
ibuprofen, reduce release of acute phase proteins and cytokines
(McMillan et al., 1995; Preston et al., 1995; Wigmore et al.,
1995). In animal studies, inhibition of prostaglandin synthesis
attenuated tumor progression and decreased incidence of can-
cer cachexia (Gelin et al., 1991a,b). One possible explanation
is that cytokines depend on signal transduction mediated by
eicosanoids; NSAIDs inhibit prostaglandin synthesis and thereby
block downstream effects of systemic inflammation. Lundholm
et al. demonstrated that indomethacin use may prolong sur-
vival in cachectic patients with metastatic solid tumors, including
pancreatic cancer (Lundholm et al., 1994). Other controlled clin-
ical trials have shown that ibuprofen can decrease CRP levels,
increase body weight and muscle mass, and improve quality
of life, especially when combined with progestogens (Wigmore
et al., 1995; McMillan et al., 1997; Lai et al., 2008). McMillan
et al. recruited 73 patients with advanced GI cancers, predomi-
nantly pancreatic cancer (67% of patients), and cancer cachexia
(McMillan et al., 1999). This multicenter randomized controlled
trial demonstrated that taking ibuprofen (1200mg/day) com-
bined with megestrol acetate (480mg/day) resulted in a signifi-
cant increase in weight and improved quality of life compared to
patients taking megestrol acetate alone (McMillan et al., 1999).
Observed side effects were similar in both groups including
venous thrombosis, upper GI bleeding, and ascites. However, due
to disease progression, the attrition rate was quite high with 63%
of patients failing to complete the 12-week assessment. These
preliminary results are promising, but further larger studies are
needed to evaluate the clinical role of NSAIDs in the management
of pancreatic cancer cachexia.
Thalidomide is known to have anti-inflammatory and
immunomodulatory properties. It has been shown to downregu-
late the production of TNF-α and other cytokines, inhibit NFκB,
downregulate COX-2, and inhibit angiogenesis (Sampaio et al.,
1991). Multiple small studies have demonstrated the efficacy of
thalidomide in improving appetite, weight gain, and sensation
of well-being (Bruera et al., 1999; Gordon et al., 2005). Gordon
et al. reports a single-center double-blind placebo-controlled
randomized clinical trial of thalidomide in 50 pancreatic can-
cer patients with cachexia. Patients were randomized to take
thalidomide 200mg/day or placebo. Patients in the thalidomide
group compared to the placebo group had a significant improve-
ment in weight (0.37 vs. −2.21 kg, P = 0.005) and lean body
mass (1.0 cm3 in arm muscle mass vs. −4.46 cm3, P = 0.002)
after 4 weeks (Gordon et al., 2005). Thalidomide was overall
well-tolerated. Adverse reactions included peripheral neuropathy,
dizziness, somnolence, constipation, rash, and possible increased
risk of venous thromboembolism in the setting of malignancy.
These initial results are positive but further clinical trials are
needed to confirm the efficacy of thalidomide in treating pancre-
atic cancer cachexia.
The omega-3 fatty acids, eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), are known to have immunomod-
ulatory properties and have been shown to suppress production
of pro-inflammatory cytokines, including IL-1, TNF-α, and IL-6
by PBMC (Meydani et al., 1993; Wigmore et al., 1997a). EPA may
also inhibit the downstream effects of LMF and PIF (Tisdale and
Beck, 1991; Tisdale, 1996; Hussey and Tisdale, 1999). Early stud-
ies associated fish oil supplementation containing both EPA and
DHA as well as high-purity EPA administration with weight stabi-
lization in patients with unresectable pancreatic cancer (Wigmore
et al., 1996, 2000b). A small pilot study also showed that the
use of EPA with oral nutritional supplements resulted in signif-
icant increase in weight, dietary intake, and performance status
in cachectic patients with advanced pancreatic cancer (Barber
et al., 1999). However, recent data from a multicenter double-
blind placebo-controlled randomized clinical trial suggest that
single agent EPA administration is not effective in treating can-
cer cachexia (Fearon et al., 2006a). Another multicenter clinical
trial comparing the effects of EPA supplement, megestrol acetate,
and combination treatment found that megestrol acetate alone is
more effective than EPA in increasing weight (Jatoi et al., 2004).
EPA was comparable to megestrol acetate with respect to appetite
gain, survival, and quality of life (Jatoi et al., 2004). Combination
therapy did not have additional benefits tomegestrol acetate alone
(Jatoi et al., 2004). The role of EPA in cancer cachexia manage-
ment remains uncertain although recent data suggest that EPA
supplementation may not be effective as a single agent or even in
combination regimens in the management of pancreatic cancer
cachexia.
Pancreatic cancer cachexia is a complex multifactorial syn-
drome. Successful management may require a multimodal
approach with nutritional supplementation and pharmacologi-
cal treatment. Recent data from a large multicenter trial suggest
that combination therapy with megestrol acetate (320mg/day),
EPA supplementation, L-carnitine (4 g/day), and thalidomide
(200mg/day) is significantly more effective in improving lean
body mass and appetite than single agents (Mantovani et al.,
2010). Combination pharmacological therapy with nutritional
supplementation in the context of best supportive care may be the
appropriate approach to pancreatic cancer cachexia management.
FUTURE DIRECTIONS
Current clinical management of pancreatic cancer cachexia is lim-
ited. None of the available therapies have shown lasting effects on
weight stabilization and improvement in survival. Development
of effective treatment for this disease remains a challenge.
Recent studies have focused on targeted therapies with anti-
inflammatory properties (Table 4). IL-6 is a promising target,
but many of the studies involving IL-6 antibodies have been in
patients with advanced non-small cell lung cancer (NSCLC) and
cachexia (Rigas et al., 2010; Schuster et al., 2010; Bayliss et al.,
2011; Ando et al., 2013). Rigas and Schuster et al. reported a
phase II randomized, double-blind, placebo-controlled trial with
NSCLC patients evaluating the safety and efficacy of ALD518
(also known as BMS-945429), a humanized monoclonal IL-6
antibody, in treating cancer cachexia. ALD518 showed promising
beneficial results. It increased hemoglobin levels and prevented
loss of lean body mass (Rigas et al., 2010; Schuster et al., 2010).
There was also a statistically significant improvement in fatigue
score in the ALD518 group vs. placebo group that persisted over
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Table 4 | Investigational drugs for the treatment of cancer cachexia.
ClinicalTrials. Title Phase Mechanism of Sponsor References
gov identifier action
NCT01206335 Open label study with
OHR/AVR118 in
advanced cancer patients
with anorexia-cachexia
II Broad spectrum
peptide-nucleic acid
immunomodulator targeting
cytokine production
(including TNF-α and IL-6)
Ohr Pharmaceutical
Inc.
ClinicalTrials.gov. Open
label study with
OHR/AVR118 in
advanced cancer
patients with
anorexia-cachexia
NCT01433263 Clinical study BYM338
for the treatment of
unintentional weight loss
in patients with cancer of
the lungs or the pancreas
II Human monoclonal
antibody against activin
receptor type 2B (ACVR2B)
Novartis
Pharmaceuticals
ClinicalTrials.gov.
Clinical study of
BYM338 for the
treatment of
unintentional weight
loss in patients with
cancer of the lung or
the pancreas
NCT01505530 A phase 2 study of
LY2495655 in participants
with pancreatic cancer
II Humanized monoclonal
antibody against myostatin
Eli Lilly and Company ClinicalTrials.gov. A
Phase 2 study of
LY2495655 in
participants with
pancreatic cancer
a 12 week period (Rigas et al., 2010). ALD518 was safe and
well-tolerated (Rigas et al., 2010; Schuster et al., 2010).
Another agent with anti-inflammatory activity is
OHR/AVR118, a broad-spectrum peptide-nucleic acid immune
modulator that targets both TNF-α and IL-6. A phase II study
involving patients with advanced cancer and cachexia showed an
improvement in anorexia, dyspepsia, strength, and depression
(Chasen et al., 2011). A phase IIb study is currently ongoing
to assess the efficacy of OHR/AVR118 in improving appetite
and enhancing weight, lean body mass, strength, and quality
of life (ClinicalTrials.gov. Open label study with OHR/AVR118
in advanced cancer patients with anorexia-cachexia). Further
studies are needed to evaluate the safety and efficacy of these
agents in patients with pancreatic cancer cachexia.
Myostatin and activin are involved in regulating skeletal mus-
cle mass and function via the activin type IIB (ActRIIB) receptor.
They inhibit myogenesis and the Akt/mTOR pathway involved in
muscle protein synthesis and increase the expression of ubiquitin
ligases to increase muscle degradation. Studies have investigated
the therapeutic potential of inhibiting myostatin and ActRIIB
in treating cancer cachexia. In pre-clinical studies, inhibition
of ActRIIB prevented muscle wasting and prolonged survival
in C-26 tumor-bearing mice (Zhou et al., 2010). BYM338 is a
myostatin inhibitor developed by Novartis (Hanover, NJ, USA)
to treat cancer cachexia. A multicenter, randomized, double-
blind, placebo-controlled phase II trial is currently underway to
investigate the efficacy of BYM338 in attenuating loss of body
mass in cachectic patients with stage IV NSCLC or stage III/IV
pancreatic cancer (ClinicalTrials.gov. Clinical study of BYM338
for the treatment of unintentional weight loss in patients with
cancer of the lung or the pancreas). LY2495655 is another
humanized antimyostatin antibody currently under investigation.
A multicenter, randomized, double-blind, placebo-controlled
phase II trial in patients with locally advanced or metastatic pan-
creatic cancer is ongoing to evaluate the efficacy of two different
doses of LY2495655 in combination with gemcitabine in improv-
ing survival as well as lean body mass and physical performance
(ClinicalTrials.gov. A Phase 2 study of LY2495655 in participants
with pancreatic cancer).
CONCLUSION
Approximately 80% of pancreatic cancer patients develop
cachexia during the disease course and up to 30% die from
cachexia-related complications (Fearon et al., 2006b; Bachmann
et al., 2009). Pancreatic cancer cachexia is a multifactorial syn-
drome characterized by anorexia and hypercatabolism that are
mediated by mechanical factors, pro-inflammatory cytokines,
neuropeptides, hormones, and tumor-derived factors. In pan-
creatic cancer, energy homeostasis is compromised and oriented
toward a continuous suppression of appetite and increased energy
expenditure. This state leads to uncompensated loss of skeletal
muscle and adipose tissue mass.
Further research is needed to elucidate the intricate mecha-
nisms involved in the induction and maintenance of pancreatic
cancer cachexia to aid in the development of future therapeutic
targets. The management of cachexia remains limited but is cur-
rently an active area of research. The use of targeted immunother-
apies have shown promising preliminary results. The future
management of pancreatic cancer cachexia will likely involve
a multimodal approach with nutritional support, combination
agents and possible targeted therapies to improve quality of life,
lean body mass, and even survival of pancreatic cancer patients.
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